Projections indicate that by 2024, the medical technology sector is set to achieve a remarkable revenue milestone, reaching US$691.50 billion. Among its diverse segments, medical devices stand out as the largest contributor, projecting a market volume of US$592.50 billion in the same year.
The trajectory of the medical technology market is poised for robust growth, with an anticipated annual growth rate of 5.59% between 2024 and 2028. Looking ahead to 2028, the market volume is forecast to soar to US$859.50 billion, underscoring the persistent demand for innovative healthcare solutions globally.
Against this backdrop of tremendous potential, let's delve into four medical technology stocks for 2024.
Therma Bright Inc. (OTC-QB: TBRIF) (TSXV: THRM) is a medical technology company driven by innovative devices and promising strategic initiatives. One of Therma Bright's most notable products is the Venowave device. This innovative solution focuses on enhancing blood circulation and preventing deep vein thrombosis (DVT). With its ability to outperform other DVT solutions on the market, the Venowave device has secured temporary Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes from the U.S. Centers for Medicare and Medicaid Services. This not only highlights its clinical effectiveness but also positions it for reimbursement in the healthcare landscape, fostering widespread adoption.
In recent developments, Therma Bright has opened distribution channels for the Venowave device, signaling a pivotal moment for the company. Pilot tests with distribution partners, coupled with doctor-patient validation, are underway. The successful outcome of these tests could lead to substantial commercial volumes, marking a crucial step in realizing the device's market potential.
Additionally, Therma Bright's proactive engagement with the U.S. Food and Drug Administration (FDA) showcases its commitment to regulatory compliance and market accessibility. Refining the Venowave device's intended use, labeling, and product description aligns with the stringent standards set by the FDA and further strengthens the company's position in the medical technology sector.
Beyond the Venowave device, Therma Bright has diversified its portfolio with the introduction of the AI-driven Digital Cough Analyzer (DCA). This technology, ready for FDA evaluation, serves as a remote therapeutic monitoring (RTM) solution. The DCA's unique features cater to both patients and medical practitioners, presenting a promising avenue for the company's future growth.
As the company progresses into 2024, updates on key business initiatives, including Venowave and the Digital Cough Analyzer, indicate positive momentum building for the company. Despite a temporary cease-trade order issued by the Ontario Securities Commission, Therma Bright's transparent communication and diligent efforts to rectify the situation, as stated in a recent tweet by the company: 'Therma Bright’s executive team is putting final touches on the year-end financial statements, MD&A, and supporting documents. We’re seeing good progress on Venowave, DCA, InStatin, and Inretio, our four key business initiatives and partnerships. $TBRIF $THRM #Venowave #AIDigitalCough'. This reflects a commitment to maintaining shareholder trust and showcases ongoing progress in key business initiatives.
Therma Bright Inc. emerges as a promising player in the medical technology sector, leveraging innovative devices and strategic endeavors to unlock substantial growth potential. The Venowave device, along with the company's commitment to regulatory compliance and diversification into advanced technologies, positions Therma Bright for success in the evolving healthcare landscape.
Profound Medical Corp. (NASDAQ:PROF) (TSX:PRN) is a prominent player in the medical device sector, specializing in customizable, incision-free therapies for the ablation of diseased tissue. The company's flagship product, TULSA-PRO, represents a groundbreaking technology that integrates real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. This special combination actively protects vital structures such as the urethra and rectum while enabling predictable, adjustable, radiation-free ablation of a prostate volume as determined by the surgeon.
TULSA-PRO has gained regulatory approvals, including CE marking, Health Canada approval, and 510(k) clearance from the U.S. Food and Drug Administration (FDA). With applications ranging from intermediate-stage cancer to palliation in locally advanced prostate cancer, TULSA-PRO demonstrates its versatility in prostate ablation, holding significant promise in various clinical scenarios.
In addition to TULSA-PRO, Profound Medical is commercializing Sonalleve, an innovative therapeutic platform designed for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has received regulatory approvals, including CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments.
Financially, Profound Medical reported strong recurring revenue growth, marking the sixth consecutive quarter of positive trends. The company's focus on TULSA-PRO commercial activities in the United States contributed to a 40% increase in recurring revenue compared to Q3-2022. Notably, TULSA-PRO's capabilities have been further enhanced by the recent 510(k) clearance of the TULSA AI Thermal Boost module, which permits surgeons to momentarily raise the ablation target temperature in order to more effectively treat aggressive cancer cells.
Despite a reported net loss for the third quarter of 2023, Profound Medical showcased prudent expense management, with total operating expenses decreasing by 18%. The company's strategic financial approach aligns with its commitment to advancing key technologies and maintaining a strong market presence.
Profound Medical's recent developments, including the extension of the HCPCS C code for TULSA-PRO in ambulatory surgical centers and the pricing of a public offering, indicate a proactive stance in furthering its commercialization efforts. The net proceeds from the offering are earmarked for advancing the commercialization of TULSA-PRO in the United States, global development of both TULSA-PRO and Sonalleve systems, and general corporate purposes.
Ventripoint Diagnostics Ltd. (OTC:VPTDF) (TSXV:VPT) has positioned itself as a frontrunner in the application of artificial intelligence (AI) to echocardiography, reshaping the landscape with its VMS products powered by proprietary KBR technology. Over a decade in development, this technology has provided precise volumetric cardiac measurements comparable to MRI at a significantly reduced cost. Notably, VMS+ seamlessly integrates with ultrasound systems from any vendor and holds regulatory market approvals in the U.S., Europe, and Canada.
On December 5, 2023, Ventripoint received a significant endorsement from the Ollie Hinkle Heart Foundation (OHHF), selecting Ventripoint's AI-powered heart-imaging technology as one of three AI systems to introduce to U.S. hospitals. This strategic move aligns with Ventripoint's mission to offer a less invasive and more efficient alternative to traditional MRI heart scans, particularly benefiting pediatric patients.
The collaboration with OHHF aims to integrate Ventripoint into the Take Heart program, initially involving 13 U.S. hospital partners, with an additional 30 expected to join. The objective is to establish Ventripoint as a standard of care, providing an affordable and rapid alternative to conventional MRI heart scans.
Furthermore, on December 12, 2023, Ventripoint entered into a global distribution and marketing agreement with ASCEND Cardiovascular, a leader in diagnostic and imaging technologies for cardiac healthcare. This partnership integrates Ventripoint's AI-powered heart-scanning technology into ASCEND's extensive network for an initial two-year term in North American markets, aiming to enhance cardiovascular health technology globally.
Ventripoint's technology, now in commercialization, has received acclaim from leading hospitals and the British Heart Foundation. The collaboration with ASCEND Cardiovascular demonstrates a commitment to ongoing innovation and excellence in cardiovascular health technology, fostering a cost-effective addition to the cardiovascular healthcare system.
In a recent development, Ventripoint released a comprehensive white paper outlining the benefits of its AI-powered technology for transforming ultrasound images into MRI-quality heart images. The white paper, authored by Dr. Alvira Macanovic, President and CEO of Ventripoint, addresses challenges in cardiac ultrasound and presents the VMS+ Knowledge-Based Reconstruction Algorithm, an AI-driven innovation that ensures accuracy on par with cardiac MRI scans.
The VMS+ system, requiring only a small number of predefined anatomical points from ultrasound images, delivers accurate heart measurements, surpassing traditional imaging methods in both accuracy and speed. This breakthrough enables cheaper and quicker echo scans than cardiac MRI, making routine cardiac monitoring more accessible and crucial for early detection and intervention in heart conditions.
As Ventripoint's AI technology gains traction in hospitals and clinics, its proven reliability and cost-effective approach position the company for significant growth in the burgeoning field of AI-powered cardiac diagnostics. Investors should keep a close eye on Ventripoint Diagnostics Ltd. as it continues to revolutionize cardiovascular healthcare with its innovative solutions.
Antibe Therapeutics Inc. (OTCQX: ATBPF) (TSX: ATE) is a clinical-stage biotechnology company focusing on developing next-generation therapies targeting inflammation resulting from various medical conditions. The company's proprietary hydrogen sulfide platform forms the basis for its current pipeline, addressing issues like gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Antibe's lead drug, otenaproxesul, is positioned as a safer alternative to opioids and current NSAIDs for acute pain, with a Phase II trial expected in calendar Q1 2024. The company's second pipeline drug, ATB-352, is tailored for a specialized pain indication. Antibe's future target is inflammatory bowel disease (IBD), aiming to provide safer and more effective therapies.
The more recent progress includes starting and finishing a pharmacokinetic/pharmacodynamic (PK/PD) study for the faster-absorbing formulation of otenaproxesul, which shows safety and helps determine treatment plans for the next Phase II trial. The study involved 36 healthy volunteers and indicated liver safety, aligning with DILIsym modeling predictions.
Antibe's strong focus on formulation, intellectual property (IP), and commercial potential, coupled with promising PK/PD data, positions the company for an exciting year ahead. The recent announcement of an Early Warrant Exercise Program aims to encourage early warrant exercise, potentially strengthening the company's financial position.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Therma Bright to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/
